2CUREX — 2cureX AB Share News
0.000.00%
Last trade - 00:00- SEK47.95m
- SEK45.85m
Brief: 2CureX Secures Patent On Its IndiTreat Test In Australia
Brief: 2CureX Q3 Pre-Tax Loss Widens To SEK 1.6 Mln
Brief: 2cureX Gets Patent In USA
Brief: 2cureX Gets Patent On Its Inditreat Test In Hong Kong
Brief: 2cureX Signs Deal With One Of Largest Private Cancer Hospitals In Nordic Countries
Brief: 2cureX Q2 Pre-Tax Loss Flat At SEK 3.1 Mln
Brief: 2cureX Gets About SEK 24.7 Million In Oversubscribed Rights Issue
Brief: 2cureX Q1 Pre-Tax Loss Narrows To SEK 1.9 Mln
Brief: 2cureX To Carry Out Rights Issue Of Max. Around SEK 24.7 Mln
Brief: 2cureX Announces Collaboration With Gibson Oncology
Brief: 2curex Receives Notice Of Allowance From The United States Patent Office
Brief: 2cureX Expands Its Activities To Preventive Cancer Medicine
Brief: 2CureX Q4 Pre-tax Loss Widens To SEK 2.9 Mln
Brief: 2Curex Names Carit J Andersen New CFO
Brief: 2Curex Q3 Loss After Tax Widens To SEK 711,000
Brief: 2cureX Gets Approval For Start Of Clinical Trial In Pancreatic Cancer
Brief: 2Curex Q2 Pre-Tax Loss Widens To SEK 3.1 Million
Brief: 2Curex AB Strengthens Its Patent Portfolio With New Approved European Patent
Brief: 2Curex AB To Present Positive Data From Clinical Study With Inditreat At Esmo In Barcelona